TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a ...

Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.

A newly engineered antibody transport vehicle targeting the transferrin receptor enables enhanced delivery of anti-amyloid ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...